Objective:

To discuss advancements in early detection and diagnostics of neurodegenerative diseases, particularly focusing on Huntington’s disease and related conditions.

Approach:

• Research Background: Amprion's journey began with Creutzfeldt-Jakob disease (CJD) research, leading to the discovery of parallels with other neurodegenerative diseases.
• Diagnostic Development: The SAAmplify-αSyn assay was developed to detect the alpha-synuclein biomarker, showing nearly 100% correlation with neuropathological findings.
• Future Directions: Exploration of a protein misfolding assay for Huntington’s disease to simplify mutation detection and enhance diagnostic capabilities.
• Technological Integration: The role of artificial intelligence and next-generation technologies in improving diagnostic accuracy and treatment personalization.

Key Findings:

• SAAmplify-αSyn can detect active disease up to 20 years before clinical diagnosis.
• The test is the first biomarker to turn positive in individuals with a genetic predisposition to Parkinson’s disease.
• Precision medicine is emerging as a new paradigm for diagnosing neurodegenerative diseases.

Interpretation:

Limitations:

• Current diagnostic challenges include the complexity of detecting various mutations in Huntington’s disease.
• The utility of a single misfolded-protein test for Huntington’s remains to be determined.

Conclusion: